

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet 1__ of 2__

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17627AP)	SERIAL NO.: Applied for
APPLICANT: Hughes	TITLE: METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF COMPOUNDS RELATED TO PROTON PUMP INHIBITORS
FILING DATE: Applied for	GROUP: Not Known

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,045,563	8/30/1977	Berntsson et al			
	AB	4,255,431	3/10/1981	Junggren et al			
	AC	4,628,098	12/9/1986	Nohara et al			
	AD	4,686,230	8/11/1987	Rainer et al			
	AE	4,758,579	7/19/1988	Kohl et al			
	AF	4,965,269	10/23/1990	Brandstrom et al			
	AG	5,021,433	6/4/1991	Alminger et al			
	AH	5,708,017	1/13/1998	Dave et al			
	AI	5,430,042	7/4/1995	Lindberg			
	AJ	5,693,818	12/2/1997	Von Unge			
	AK	6,369,085	4/9/2002	Cotton et al			
	AL	5,045,552	9/3/1991	Souda et al			
	AM	6,093,734	7/25/2000	Garst et al			
	AN	6,897,227	5/24/2005	Garst et al			
	AO	2005/0038076	2/17/2005	Garst et al			
	AP	6,559,167	5/6/2003	Garst et al			
	AQ	2005/0075371	4/7/2005	Shen et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AS	WO 00/09498	2/24/2000	PCT			
	AT	WO 02/30920	4/18/2002	PCT			
	AU	WO 02/00166	1/3/2002	PCT			

EXAMINER /Gregg Polansky/

DATE CONSIDERED

06/16/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet 1__ of 2__

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17627AP)	SERIAL NO.: Applied for
APPLICANT: Hughes	TITLE: METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF COMPOUNDS RELATED TO PROTON PUMP INHIBITORS
FILING DATE: Applied for	GROUP: Not Known

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	AV	Design of Prodrugs (Bundgaard H. ed.) 1985 Elsevier Science Publishers B. V. (Biomedical Division), Chapter 1; Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities (Hans Bundgaard)
	AW	Bundgaard et al. Int. J. of Pharmaceutics 22 (1984) 45-56 (Elsevier)
	AX	Bundgaard et al. Int. J. of Pharmaceutics 29 (1986) 19-28 (Elsevier)
	AY	Bundgaard et al. J. Med. Chem. 32 (1989) 2503-2507
	AZ	Chem. Abstracts 95, 138493f (Bundgaard et al.)
	BA	Chem. Abstracts 95, 138592n (Bundgaard et al.)
	BB	Chem. Abstracts 93, 137935y (Bundgaard et al.)
	BC	Chem. Abstracts 110, 57664p (Alminger et al.)
	BD	Chem. Abstracts 115, 64029s (Buur et al.)
	BE	Chem. Abstracts 115, 189582y (Hansen et al.)
	BF	Chem. Abstracts 117, 55790x (Jensen et al.)
	BG	Chem. Abstracts 123, 17593b (Thomsen et al.)
	BH	Sih., et al. (Journal of Medicinal Chemistry, 1991, vol. 34, pp 1049-1062)
	BI	Handbook On Injectable Drugs (11th edition), edited by Lawrence A. Trissel, (Chicago: Lippincott Brothers Book Company, January 15, 2001).
No page numbers cited. /GP/		
	BJ	http://www.astazenecca.co.uk/downloads/Loselinfusion(0470).pdf

No publication date. /GP/

EXAMINER /Gregg Polansky/DATE CONSIDERED 06/16/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./